Hyperferritinemia is another surrogate marker of advanced liver disease

Patients with chronic hepatitis C virus (HCV) infection often have elevated serum iron indices, but these do not accurately reflect hepatic iron content, nor are they able to predict clinically important endpoints, such as progression of fibrosis and responsiveness to interferon-based regimens. Studies that attempt to link iron and the course of chronic hepatitis C have been inconclusive. In chronic hepatitis C, steatosis is a common histological finding, occurring in 30%-70% of such patients. The biological mechanism underlying steatosis in HCV infection is not definitively understood, and is considered to be multifactorial with metabolic mechanisms, including insulin resistance and iron overload.

A research article to be published on May 7, 2009 in the World Journal of Gastroenterology addresses this question. The research team led by Professor Licata from Gastroenterology and Hepatology Unit of Palermo University analyzed in a cross-sectional study, a cohort of non-obese, non-alcoholic patients with compensated chronic liver disease characterized by elevated serum ferritin levels, of varying etiology, excluding hemochromatosis, to reassess the link between hyperferritinemia and other markers of the metabolic syndrome, mainly steatosis. All data provide further evidence that hyperferritinemia might be another surrogate marker of advanced liver disease of any etiology.

More information: Licata A, Nebbia ME, Cabibbo G, Lo Iacono G, Barbaria F, Brucato V, Alessi N, Porrovecchio S, Di Marco V, Craxě A, Cammà C. Hyperferritinemia is a risk factor for steatosis in chronic liver disease. World J Gastroenterol 2009; 15(17): 2132-2138 http://www.wjgnet.com/1007-9327/15/2132.asp

Source: World Journal of Gastroenterology (news : web)